From the Departments of Neurosurgery (P.H., O.G., S.S.D., M.J.K., C.M.S.)
Department of Neurosurgery (P.H., G.M.W., I.M., C.M.S.), Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania.
AJNR Am J Neuroradiol. 2023 Jun;44(6):681-686. doi: 10.3174/ajnr.A7862. Epub 2023 May 11.
IV thrombolysis with alteplase before mechanical thrombectomy for emergent large-vessel-occlusion stroke is associated with access-site bleeding complications. However, the incidence of femoral access-site complications with tenecteplase before mechanical thrombectomy requires exploration. Here, femoral access-site complications with tenecteplase versus alteplase before mechanical thrombectomy for large-vessel-occlusion stroke were compared.
All patients receiving IV thrombolytics before mechanical thrombectomy for large-vessel-occlusion stroke who presented from January 2020 to August 2022 were reviewed. In May 2021, our health care system switched from alteplase to tenecteplase as the primary thrombolytic for all patients with stroke, facilitating the comparison of alteplase-versus-tenecteplase femoral access-site complication rates. Major (requiring surgery) and minor (managed conservatively) access-site complications were assessed.
One hundred thirty-nine patients underwent transfemoral mechanical thrombectomy for large-vessel-occlusion stroke, of whom 46/139 (33.1%) received tenecteplase and 93/139 (66.9%) received alteplase. In all cases ( = 139), an 8F sheath was inserted without sonographic guidance, and vascular closure was obtained with an Angio-Seal. Baseline demographics, concomitant antithrombotic medications, and periprocedural coagulation lab findings were similar between groups. The incidence of conservatively managed groin hematomas (2.2% versus 4.3%), delayed access-site oozing requiring manual compression (6.5% versus 2.2%), and arterial occlusion requiring surgery (2.2% versus 1.1%) was similar between the tenecteplase and alteplase groups, respectively ( = not significant). No dissection, arteriovenous fistula, or retroperitoneal hematoma was observed.
Tenecteplase compared with alteplase before mechanical thrombectomy for large-vessel-occlusion stroke is not associated with an alteration in femoral access-site complication rates.
在机械取栓前进行 IV 重组组织型纤溶酶原激活剂(alteplase)溶栓治疗急性大动脉闭塞性脑卒中,与入路部位出血并发症相关。然而,机械取栓前使用替奈普酶(tenecteplase)的股动脉入路并发症发生率仍需要进一步探讨。本研究比较了机械取栓前使用替奈普酶和 alteplase 治疗大动脉闭塞性脑卒中的股动脉入路并发症。
回顾了 2020 年 1 月至 2022 年 8 月期间所有接受机械取栓前 IV 溶栓治疗的大动脉闭塞性脑卒中患者。2021 年 5 月,我们的医疗系统将替奈普酶作为所有脑卒中患者的主要溶栓药物,取代 alteplase,从而便于比较 alteplase 与 tenecteplase 的股动脉入路并发症发生率。评估主要(需要手术)和次要(保守治疗)入路并发症。
139 例患者因大动脉闭塞性脑卒中接受经股动脉机械取栓治疗,其中 46/139(33.1%)例患者接受替奈普酶治疗,93/139(66.9%)例患者接受 alteplase 治疗。所有患者(n=139)均在未行超声引导下插入 8F 鞘,并用 Angio-Seal 血管闭合装置闭合血管。两组患者的基线人口统计学特征、同时使用的抗血栓药物和围手术期凝血实验室检查结果相似。两组患者保守治疗的腹股沟血肿(2.2% vs. 4.3%)、需要手动按压的延迟性入路部位渗血(6.5% vs. 2.2%)和需要手术的动脉闭塞(2.2% vs. 1.1%)发生率相似(无显著差异)。未观察到夹层、动静脉瘘或腹膜后血肿。
与机械取栓前使用 alteplase 相比,替奈普酶治疗大动脉闭塞性脑卒中并不增加股动脉入路并发症的发生率。